APLS

Apellis Pharmaceuticals Inc

Jan 23 • 04:00PM ET

21.75

-0.25 -1.14 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN SRPT MRNA BMRN EXEL VRTX PBYI UTHR KURA

| Held by: VTI XBI VB VBK VXF IBB IWP FXH PINK SCHA

Index	-	P/E	73.26	EPS (ttm)	0.30	Insider Own	17.88%	Shs Outstand	126.50M	Perf Week	5.94%
Market Cap	2.75B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-2.31%	Shs Float	103.91M	Perf Month	-14.37%
Enterprise Value	2.75B	PEG	-	EPS next Q	-0.38	Inst Own	99.25%	Short Float	15.51%	Perf Quarter	-22.71%
Income	44.99M	P/S	2.71	EPS this Y	115.98%	Inst Trans	-1.38%	Short Ratio	5.74	Perf Half Y	8.26%
Sales	1.02B	P/B	6.86	EPS next Y	-519.87%	ROA	4.59%	Short Interest	16.12M	Perf YTD	-13.42%
Book/sh	3.17	P/C	5.73	EPS next 5Y	50.02%	ROE	14.10%	52W High	31.17 -30.22%	Perf Year	-28.43%
Cash/sh	3.80	P/FCF	34.99	EPS past 3/5Y	43.47% 20.08%	ROIC	5.80%	52W Low	16.10 35.09%	Perf 3Y	-57.72%
Dividend Est.	-	EV/EBITDA	33.46	Sales past 3/5Y	127.27% -	Gross Margin	88.72%	Volatility	5.13% 5.54%	Perf 5Y	-58.49%
Dividend TTM	-	EV/Sales	2.70	EPS Y/Y TTM	116.92%	Oper. Margin	7.91%	ATR (14)	1.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.10	Sales Y/Y TTM	42.11%	Profit Margin	4.43%	RSI (14)	44.28	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	3.54	EPS Q/Q	458.67%	SMA20	-7.62%	Beta	0.25	Target Price	34.50
Payout	-	Debt/Eq	1.18	Sales Q/Q	132.98%	SMA50	-4.50%	Rel Volume	0.79	Prev Close	22.00
Employees	710	LT Debt/Eq	0.93	Earnings	Oct 30 BMO	SMA200	-0.66%	Avg Volume	2.81M	Price	21.75
IPO	Nov 09, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.78% 1.10%	Trades		Volume	2,214,978	Change	-1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-21-26	Upgrade	BofA Securities	Neutral → Buy	$28
Nov-06-25	Initiated	Wolfe Research	Peer Perform
Oct-15-25	Initiated	Wells Fargo	Overweight	$32
Sep-26-25	Downgrade	Goldman	Neutral → Sell	$18
May-09-25	Downgrade	Raymond James	Strong Buy → Outperform	$52
May-09-25	Downgrade	BofA Securities	Buy → Neutral	$23
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$44
Dec-17-24	Downgrade	Goldman	Buy → Neutral	$36
Nov-21-24	Initiated	Morgan Stanley	Equal-Weight	$31
Oct-25-24	Initiated	RBC Capital Mkts	Sector Perform	$25
Oct-16-24	Initiated	William Blair	Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
May-31-24	Initiated	Piper Sandler	Neutral	$46
Feb-05-24	Upgrade	Jefferies	Hold → Buy	$68 → $80
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy	$74
Nov-02-23	Initiated	Mizuho	Neutral	$42
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight	$60 → $81
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$34 → $64
Aug-29-23	Reiterated	Citigroup	Buy	$45 → $54

Show Previous Ratings

Jan-21-26 01:14PM	Apellis Valuation Ignores Empaveli Potential, Says Analyst (Benzinga)
Jan-17-26 05:36AM	Is Apellis Pharmaceuticals FDA Win Just the Beginning? (24/7 Wall St.)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 01:04PM	Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? (Benzinga) -8.06%
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) -15.02%
03:37PM	Loading…
03:37PM	Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference (MarketBeat)
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
07:00AM	Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 07:00AM	Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 11:30AM	Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 05:05PM	The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI (pegcetacoplan) for C3G and Primary IC-MPGN (GlobeNewswire)
11:30AM	Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? (Zacks)
Nov-30-25 12:26AM	Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy (Insider Monkey)
Nov-25-25 08:39AM	Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges (Insider Monkey)
07:00AM	Loading…
07:00AM	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-25 07:00AM	Apellis Announces 5-Year GALE Data Showing SYFOVRE (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years (GlobeNewswire)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-05-25 07:00AM	Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-30-25 04:32PM	Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -31.01%
09:30AM	Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
07:05AM	Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-29-25 09:36AM	Earnings To Watch: Apellis Pharmaceuticals Inc (APLS) Reports Q3 2025 Result (GuruFocus.com)
Oct-27-25 10:00AM	Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) +5.72%
Oct-23-25 10:00AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-20-25 07:00AM	New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week (GlobeNewswire) +10.40%
Oct-16-25 07:00AM	Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-15-25 02:57PM	Wall Street Analysts Just Upgraded These Hot Stocks: UBER, LOGI, DASH, APLS (24/7 Wall St.) +8.94%
04:13AM	Loading…
Sep-30-25 04:13AM	Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) (Insider Monkey)
Aug-27-25 07:00AM	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 01:17AM	FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals' Stock Higher for the Week (Insider Monkey) +11.21%
Aug-01-25 01:23PM	Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target (Insider Monkey)
Jul-31-25 09:30AM	Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +17.58%
07:05AM	Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-30-25 09:41AM	What To Expect From Apellis Pharmaceuticals Inc (APLS) Q2 2025 Earnings (GuruFocus.com)
08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
Jul-29-25 08:45AM	Repligen (RGEN) Lags Q2 Earnings Estimates (Zacks)
Jul-28-25 07:19PM	FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older (GlobeNewswire)
10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 07:00AM	Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-16-25 11:54AM	Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag (Zacks)
Jul-15-25 07:00AM	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting (GlobeNewswire)
Jul-09-25 12:55AM	Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M (Insider Monkey) +7.38%
Jul-06-25 04:15AM	Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating (Insider Monkey)
Jul-02-25 10:08PM	Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing (Insider Monkey)
10:32AM	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
Jul-01-25 07:40AM	Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) (PR Newswire)
07:00AM	Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan) (GlobeNewswire)
Jun-13-25 11:30AM	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks)
Jun-09-25 05:31AM	Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN (Clinical Trials Arena)
Jun-07-25 09:25AM	Apellis, Sobi present data from open-label period of Phase 3 VALIANT study (TipRanks)
Jun-06-25 11:31AM	Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? (Zacks)
09:15AM	Apellis and Sobi Announce EMPAVELI (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN (GlobeNewswire)
Jun-04-25 07:00AM	Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 02:23AM	Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday (Insider Monkey)
May-09-25 10:35AM	Apellis price target lowered to $20 from $28 at Scotiabank (TipRanks)
09:18AM	Apellis Pharmaceuticals downgraded by Raymond James due to added uncertainty (Investing.com)
08:46AM	Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? (Insider Monkey)
May-08-25 10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
03:13AM	Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ... (GuruFocus.com)
12:45AM	Q1 2025 Apellis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-07-25 06:09PM	Why Apellis Pharmaceuticals Wilted on Wednesday (Motley Fool) -5.91%
01:18PM	Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-06-25 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-05-25 08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks) +5.49%
07:00AM	Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 08:24PM	Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey)
10:01AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-23-25 12:56PM	Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-21-25 07:00AM	Apellis Announces Craig Wheeler to Join the Board of Directors (GlobeNewswire)
Apr-15-25 07:20AM	BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-02-25 09:11AM	APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag (Zacks)
04:55AM	FDA accepts priority review of Apellis Empaveli sNDA for kidney diseases (Pharmaceutical Technology)
Apr-01-25 07:00AM	Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI (pegcetacoplan) for C3G and Primary IC-MPGN (GlobeNewswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 05:41PM	Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-22-25 11:41AM	Morgan Stanley says Fabhaltas label leaves opportunity for Apellis Empaveli (TipRanks)
Mar-21-25 01:13PM	Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy (SeekingAlpha)
Mar-05-25 02:04PM	Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst (Benzinga)
Mar-01-25 02:08AM	Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
01:29AM	Q4 2024 Apellis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-25 09:30AM	Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-27-25 07:11AM	What To Expect From Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 07:00AM	Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-23-25 01:31PM	Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-21-25 10:00AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-20-25 12:08PM	Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now? (Insider Monkey)
02:00AM	Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli (pegcetacoplan) for C3G and Primary IC-MPGN (GlobeNewswire)
Feb-18-25 04:12PM	Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January (Insider Monkey)
Feb-14-25 07:00AM	Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-11-25 02:03PM	Why Insiders Are Selling Apellis Pharmaceuticals, Inc. (APLS) Recently (Insider Monkey)
Feb-04-25 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.52%

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baumal Caroline	Chief Medical Officer	Jan 22 '26	Sale	21.77	2,797	60,878	86,527	Jan 23 04:13 PM
Chopas James George	VP/Chief Accounting Officer	Jan 22 '26	Sale	21.77	2,064	44,924	49,805	Jan 23 04:12 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 22 '26	Sale	21.77	3,371	73,371	78,353	Jan 23 04:11 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 22 '26	Sale	21.77	5,928	129,025	1,151,382	Jan 23 04:10 PM
Francois Cedric	Chief Executive Officer	Jan 22 '26	Sale	21.77	27,192	591,845	286,045	Jan 23 04:09 PM
Nicholson Nur	Chief Technical Officer	Jan 22 '26	Sale	21.77	7,725	168,138	71,118	Jan 23 04:08 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 22 '26	Sale	21.77	10,287	223,901	93,901	Jan 23 04:07 PM
Watson David O.	General Counsel	Jan 22 '26	Sale	21.77	7,832	170,467	88,531	Jan 23 04:05 PM
Watson David O.	Officer	Jan 22 '26	Proposed Sale	21.77	7,832	170,467		Jan 22 04:42 PM
Deschatelets Pascal	Officer	Jan 22 '26	Proposed Sale	21.77	5,928	129,025		Jan 22 04:42 PM
Sullivan Timothy Eugene	Officer	Jan 22 '26	Proposed Sale	21.77	10,287	223,901		Jan 22 04:37 PM
DeLong Mark Jeffrey	Officer	Jan 22 '26	Proposed Sale	21.77	3,371	73,371		Jan 22 04:32 PM
Francois Cedric	Officer	Jan 22 '26	Proposed Sale	21.77	27,192	591,845		Jan 22 04:31 PM
Nicholson Nur	Officer	Jan 22 '26	Proposed Sale	21.77	7,725	168,138		Jan 22 04:29 PM
Chopas James George	Officer	Jan 22 '26	Proposed Sale	21.77	2,064	44,924		Jan 22 04:24 PM
Baumal Caroline	Officer	Jan 22 '26	Proposed Sale	21.77	2,797	60,878		Jan 22 04:14 PM
Baumal Caroline	Chief Medical Officer	Jan 20 '26	Sale	19.79	1,882	37,250	89,324	Jan 21 04:19 PM
Chopas James George	VP/Chief Accounting Officer	Jan 20 '26	Sale	19.79	726	14,370	51,869	Jan 21 04:18 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 20 '26	Sale	19.79	1,334	26,404	81,724	Jan 21 04:17 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 20 '26	Sale	19.79	909	17,992	1,157,310	Jan 21 04:16 PM
Francois Cedric	Chief Executive Officer	Jan 20 '26	Sale	19.79	8,182	161,946	313,237	Jan 21 04:14 PM
Nicholson Nur	Chief Technical Officer	Jan 20 '26	Sale	19.79	2,203	43,604	78,843	Jan 21 04:12 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 20 '26	Sale	19.79	2,892	57,241	104,188	Jan 21 04:10 PM
Watson David O.	General Counsel	Jan 20 '26	Sale	19.79	2,475	48,987	96,363	Jan 21 04:08 PM
Nicholson Nur	Officer	Jan 20 '26	Proposed Sale	19.79	2,203	43,604		Jan 20 03:42 PM
Watson David O.	Officer	Jan 20 '26	Proposed Sale	19.79	2,475	48,987		Jan 20 03:41 PM
Francois Cedric	Officer	Jan 20 '26	Proposed Sale	19.79	8,182	161,946		Jan 20 03:31 PM
DeLong Mark Jeffrey	Officer	Jan 20 '26	Proposed Sale	19.79	1,334	26,404		Jan 20 03:26 PM
Deschatelets Pascal	Officer	Jan 20 '26	Proposed Sale	19.79	909	17,992		Jan 20 03:26 PM
Baumal Caroline	Officer	Jan 20 '26	Proposed Sale	19.79	1,882	37,250		Jan 20 03:19 PM
Sullivan Timothy Eugene	Officer	Jan 20 '26	Proposed Sale	19.79	2,892	57,241		Jan 20 03:10 PM
Chopas James George	Officer	Jan 20 '26	Proposed Sale	19.79	726	14,370		Jan 20 03:10 PM
Chopas James George	VP/Chief Accounting Officer	Jan 13 '26	Sale	22.19	873	19,369	52,595	Jan 15 04:34 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 13 '26	Sale	22.19	1,780	39,493	83,058	Jan 15 04:33 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 13 '26	Sale	22.19	2,277	50,520	1,158,219	Jan 15 04:32 PM
Francois Cedric	Chief Executive Officer	Jan 13 '26	Sale	22.19	10,186	225,999	321,419	Jan 15 04:31 PM
Nicholson Nur	Chief Technical Officer	Jan 13 '26	Sale	22.19	2,618	58,086	81,046	Jan 15 04:30 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 13 '26	Sale	22.19	3,856	85,554	107,080	Jan 15 04:29 PM
Watson David O.	General Counsel	Jan 13 '26	Sale	22.19	5,780	128,242	98,838	Jan 15 04:28 PM
Nicholson Nur	Officer	Jan 13 '26	Proposed Sale	22.19	2,618	58,086		Jan 13 04:12 PM
Chopas James George	Officer	Jan 13 '26	Proposed Sale	22.19	873	19,369		Jan 13 03:58 PM
Watson David O.	Officer	Jan 13 '26	Proposed Sale	22.19	5,780	128,242		Jan 13 03:55 PM
DeLong Mark Jeffrey	Officer	Jan 13 '26	Proposed Sale	22.19	1,780	39,493		Jan 13 03:53 PM
Deschatelets Pascal	Officer	Jan 13 '26	Proposed Sale	22.19	2,277	50,520		Jan 13 03:48 PM
Francois Cedric	Officer	Jan 13 '26	Proposed Sale	22.19	10,186	225,999		Jan 13 03:45 PM
Sullivan Timothy Eugene	Officer	Jan 13 '26	Proposed Sale	22.19	3,856	85,554		Jan 13 03:40 PM
Watson David O.	General Counsel	Jan 07 '26	Option Exercise	14.95	888	13,276	104,618	Jan 09 06:48 PM
Baumal Caroline	Chief Medical Officer	Jan 05 '26	Sale	25.53	3,020	77,097	91,206	Jan 06 04:06 PM
Baumal Caroline	Officer	Jan 05 '26	Proposed Sale	25.53	3,020	77,097		Jan 05 03:06 PM
Watson David O.	General Counsel	Dec 16 '25	Sale	24.49	5,000	122,450	103,730	Dec 18 04:06 PM
Watson David O.	Officer	Dec 16 '25	Proposed Sale	24.49	5,000	122,450		Dec 16 10:24 AM
Watson David O.	General Counsel	Nov 17 '25	Sale	20.06	5,000	100,300	108,730	Nov 18 10:05 AM
Watson David O.	Officer	Nov 17 '25	Proposed Sale	20.06	5,000	100,300		Nov 17 10:28 AM
Sullivan Timothy Eugene	Chief Financial Officer	Oct 21 '25	Option Exercise	10.03	10,000	100,300	120,936	Oct 23 04:20 PM
Sullivan Timothy Eugene	Chief Financial Officer	Oct 21 '25	Sale	28.03	10,000	280,300	110,936	Oct 23 04:20 PM
Sullivan Timothy Eugene	Officer	Oct 21 '25	Proposed Sale	28.03	10,000	280,300		Oct 21 11:24 AM
Watson David O.	General Counsel	Oct 16 '25	Sale	25.22	5,000	126,100	113,730	Oct 17 04:15 PM
Watson David O.	Officer	Oct 16 '25	Proposed Sale	25.22	5,000	126,100		Oct 16 09:52 AM
Dunlop A. Sinclair	Director	Oct 10 '25	Sale	23.72	31,092	737,536	3,837	Oct 15 08:12 PM
Dunlop A. Sinclair	Director	Sep 30 '25	Sale	22.58	31,092	702,057	33,979	Oct 02 04:02 PM
Dunlop A. Sinclair	Director	Sep 19 '25	Sale	22.95	31,092	713,561	68,908	Sep 19 09:17 PM
Dunlop A. Sinclair	Director	Sep 19 '25	Proposed Sale	22.95	93,276	2,140,917		Sep 19 04:15 PM
Watson David O.	General Counsel	Sep 16 '25	Sale	24.34	5,000	121,700	118,730	Sep 18 04:01 PM
Chopas James George	VP/Chief Accounting Officer	Sep 15 '25	Sale	24.19	189	4,572	53,468	Sep 17 08:08 PM
Watson David O.	Officer	Sep 16 '25	Proposed Sale	24.34	5,000	121,700		Sep 16 10:47 AM
Chopas James George	Officer	Sep 15 '25	Proposed Sale	24.19	189	4,572		Sep 15 03:20 PM
Watson David O.	General Counsel	Sep 10 '25	Sale	26.17	20,000	523,400	50,136	Sep 12 04:01 PM
THE DAVID O WATSON IRREV TR OF	Officer	Sep 10 '25	Proposed Sale	26.17	20,000	523,436		Sep 10 04:23 PM
Sullivan Timothy Eugene	Chief Financial Officer	Sep 08 '25	Option Exercise	10.03	15,000	150,450	143,665	Sep 10 04:02 PM
Sullivan Timothy Eugene	Chief Financial Officer	Sep 08 '25	Sale	27.86	32,729	911,830	110,936	Sep 10 04:02 PM
Sullivan Timothy Eugene	Chief Financial Officer	Sep 08 '25	Sale	27.83	10,000	278,300	60,396	Sep 10 04:02 PM
Timothy E Sullivan Irrevocable	Officer	Sep 08 '25	Proposed Sale	28.00	10,000	280,000		Sep 08 04:26 PM
Sullivan Timothy Eugene	Officer	Sep 08 '25	Proposed Sale	27.86	32,729	911,830		Sep 08 09:55 AM
Chopas James George	VP/Chief Accounting Officer	Sep 02 '25	Sale	28.08	548	15,386	53,657	Sep 03 01:06 PM
Chopas James George	Officer	Sep 02 '25	Proposed Sale	28.08	548	15,386		Sep 02 03:56 PM
Francois Cedric	Chief Executive Officer	Aug 27 '25	Sale	28.19	175,037	4,934,293	357,909	Aug 29 04:19 PM
Francois Cedric	Chief Executive Officer	Aug 28 '25	Sale	28.39	49,963	1,418,450	307,946	Aug 29 04:19 PM
The Cedric Francois Irrevocabl	Officer	Aug 27 '25	Proposed Sale	28.72	225,000	6,462,500		Aug 27 05:28 PM
Watson David O.	General Counsel	Aug 18 '25	Sale	27.80	5,000	139,000	123,730	Aug 19 04:40 PM
Watson David O.	Officer	Aug 18 '25	Proposed Sale	27.80	5,000	139,000		Aug 18 11:38 AM
Francois Cedric	Chief Executive Officer	Jul 17 '25	Option Exercise	4.31	8,997	38,777	351,330	Jul 18 04:02 PM
Francois Cedric	Chief Executive Officer	Jul 17 '25	Sale	20.21	19,725	398,735	331,605	Jul 18 04:02 PM
Watson David O.	General Counsel	Jul 16 '25	Sale	19.55	5,000	97,750	128,730	Jul 18 04:00 PM
Francois Cedric	Officer	Jul 17 '25	Proposed Sale	20.15	19,725	397,552		Jul 17 04:56 PM
Francois Cedric	Chief Executive Officer	Jul 14 '25	Option Exercise	4.31	65,203	281,025	480,898	Jul 16 04:11 PM
Francois Cedric	Chief Executive Officer	Jul 15 '25	Option Exercise	4.31	800	3,448	344,233	Jul 16 04:11 PM
Francois Cedric	Chief Executive Officer	Jul 14 '25	Sale	20.19	137,465	2,774,923	343,433	Jul 16 04:11 PM
Francois Cedric	Chief Executive Officer	Jul 15 '25	Sale	20.09	1,900	38,168	342,333	Jul 16 04:11 PM
Watson David O.	Officer	Jul 16 '25	Proposed Sale	19.55	5,000	97,750		Jul 16 04:10 PM
Francois Cedric	Officer	Jul 15 '25	Proposed Sale	20.09	1,900	38,168		Jul 15 04:41 PM
Francois Cedric	Officer	Jul 14 '25	Proposed Sale	20.19	137,465	2,774,922		Jul 14 04:50 PM
Watson David O.	General Counsel	Jun 16 '25	Sale	18.77	5,000	93,850	133,730	Jun 18 08:49 AM
Watson David O.	Officer	Jun 16 '25	Proposed Sale	18.77	5,000	93,850		Jun 16 10:38 AM
Deschatelets Pascal	Chief Scientific Officer	May 21 '25	Option Exercise	3.76	12,780	48,053	1,160,496	May 22 01:19 PM
Townsend Adam J.	Former Officer	May 12 '25	Proposed Sale	17.76	220,961	3,924,267		May 12 02:22 PM
Chopas James George	VP/Chief Accounting Officer	Mar 17 '25	Sale	24.82	183	4,543	47,955	Mar 18 12:27 PM
Chopas James George	Officer	Mar 17 '25	Proposed Sale	24.82	183	4,543		Mar 17 03:18 PM
Watson David O.	General Counsel	Mar 05 '25	Sale	25.10	5,569	139,789	138,730	Mar 06 05:17 PM
DAVID OSBORNE WATSON	Officer	Mar 05 '25	Proposed Sale	25.10	5,569	139,789		Mar 05 04:22 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Feb 11 '25	Sale	28.54	363	10,360	83,945	Feb 12 01:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLS

Apellis Pharmaceuticals Inc

Upgrade your FINVIZ experience